Review



fk886  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress fk886
    Comparison of the survival rate differences in the breast cancer cell line MDA-MB-231 after co-treatment with various misfolding p53 aggregation inhibitors and doxorubicin. ( A ) Cells were treated with the chemotherapy drug doxorubicin (DOX, 1 μM) and the following concentrations of each misfolding p53 aggregation inhibitor: HSP90 inhibitor (IPI-504, 5 μM), HSP70 inhibitor (VER-155008, 10 μM), LOX inhibitor (BAPN, 100 μM), and NAMPT inhibitor <t>(FK886,</t> 10 μM). After 48 h of drug treatment, cell survival rates were assessed using CCK8 reagent. DMSO only was calculated as 100% to normalize other treatment conditions. Results are presented as mean ± SD, n = 3 (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., p > 0.05). ( B ) Calculation of the drug interaction coefficient (CDI) between doxorubicin and HSP90 inhibitor (IPI-504) in MDA-MB-231 cells. According to the cell survival rate calculations from the CCK8 assay, the CDI value is 1.17, indicating that doxorubicin and IPI-504 have no synergistic cytotoxic effect on MDA-MB-231 cells. ( C ) Calculation of CDI for doxorubicin and HSP70 inhibitor (VER-155008) in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.61, indicating that doxorubicin and VER-155008 exhibit a significant synergistic cytotoxic effect on MDA-MB-231 cells. ( D ) Calculation of CDI between doxorubicin and the LOX inhibitor BAPN in MDA-MB-231 cells. According to the CCK8 assay cell survival rate calculations, the CDI value is 1.14, indicating that doxorubicin and BAPN had no drug synergistic cytotoxic effect on MDA-MB-231 cells. ( E ) Calculation of CDI between doxorubicin and FK886 in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.94, indicating that doxorubicin and FK886 had a synergistic cytotoxic effect on MDA-MB-231 cells.
    Fk886, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fk886/product/MedChemExpress
    Average 94 stars, based on 4 article reviews
    fk886 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells"

    Article Title: Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells

    Journal: Biomedicines

    doi: 10.3390/biomedicines13051034

    Comparison of the survival rate differences in the breast cancer cell line MDA-MB-231 after co-treatment with various misfolding p53 aggregation inhibitors and doxorubicin. ( A ) Cells were treated with the chemotherapy drug doxorubicin (DOX, 1 μM) and the following concentrations of each misfolding p53 aggregation inhibitor: HSP90 inhibitor (IPI-504, 5 μM), HSP70 inhibitor (VER-155008, 10 μM), LOX inhibitor (BAPN, 100 μM), and NAMPT inhibitor (FK886, 10 μM). After 48 h of drug treatment, cell survival rates were assessed using CCK8 reagent. DMSO only was calculated as 100% to normalize other treatment conditions. Results are presented as mean ± SD, n = 3 (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., p > 0.05). ( B ) Calculation of the drug interaction coefficient (CDI) between doxorubicin and HSP90 inhibitor (IPI-504) in MDA-MB-231 cells. According to the cell survival rate calculations from the CCK8 assay, the CDI value is 1.17, indicating that doxorubicin and IPI-504 have no synergistic cytotoxic effect on MDA-MB-231 cells. ( C ) Calculation of CDI for doxorubicin and HSP70 inhibitor (VER-155008) in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.61, indicating that doxorubicin and VER-155008 exhibit a significant synergistic cytotoxic effect on MDA-MB-231 cells. ( D ) Calculation of CDI between doxorubicin and the LOX inhibitor BAPN in MDA-MB-231 cells. According to the CCK8 assay cell survival rate calculations, the CDI value is 1.14, indicating that doxorubicin and BAPN had no drug synergistic cytotoxic effect on MDA-MB-231 cells. ( E ) Calculation of CDI between doxorubicin and FK886 in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.94, indicating that doxorubicin and FK886 had a synergistic cytotoxic effect on MDA-MB-231 cells.
    Figure Legend Snippet: Comparison of the survival rate differences in the breast cancer cell line MDA-MB-231 after co-treatment with various misfolding p53 aggregation inhibitors and doxorubicin. ( A ) Cells were treated with the chemotherapy drug doxorubicin (DOX, 1 μM) and the following concentrations of each misfolding p53 aggregation inhibitor: HSP90 inhibitor (IPI-504, 5 μM), HSP70 inhibitor (VER-155008, 10 μM), LOX inhibitor (BAPN, 100 μM), and NAMPT inhibitor (FK886, 10 μM). After 48 h of drug treatment, cell survival rates were assessed using CCK8 reagent. DMSO only was calculated as 100% to normalize other treatment conditions. Results are presented as mean ± SD, n = 3 (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., p > 0.05). ( B ) Calculation of the drug interaction coefficient (CDI) between doxorubicin and HSP90 inhibitor (IPI-504) in MDA-MB-231 cells. According to the cell survival rate calculations from the CCK8 assay, the CDI value is 1.17, indicating that doxorubicin and IPI-504 have no synergistic cytotoxic effect on MDA-MB-231 cells. ( C ) Calculation of CDI for doxorubicin and HSP70 inhibitor (VER-155008) in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.61, indicating that doxorubicin and VER-155008 exhibit a significant synergistic cytotoxic effect on MDA-MB-231 cells. ( D ) Calculation of CDI between doxorubicin and the LOX inhibitor BAPN in MDA-MB-231 cells. According to the CCK8 assay cell survival rate calculations, the CDI value is 1.14, indicating that doxorubicin and BAPN had no drug synergistic cytotoxic effect on MDA-MB-231 cells. ( E ) Calculation of CDI between doxorubicin and FK886 in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.94, indicating that doxorubicin and FK886 had a synergistic cytotoxic effect on MDA-MB-231 cells.

    Techniques Used: Comparison, CCK-8 Assay



    Similar Products

    fk886  (MedChemExpress)
    94
    MedChemExpress fk886
    Comparison of the survival rate differences in the breast cancer cell line MDA-MB-231 after co-treatment with various misfolding p53 aggregation inhibitors and doxorubicin. ( A ) Cells were treated with the chemotherapy drug doxorubicin (DOX, 1 μM) and the following concentrations of each misfolding p53 aggregation inhibitor: HSP90 inhibitor (IPI-504, 5 μM), HSP70 inhibitor (VER-155008, 10 μM), LOX inhibitor (BAPN, 100 μM), and NAMPT inhibitor <t>(FK886,</t> 10 μM). After 48 h of drug treatment, cell survival rates were assessed using CCK8 reagent. DMSO only was calculated as 100% to normalize other treatment conditions. Results are presented as mean ± SD, n = 3 (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., p > 0.05). ( B ) Calculation of the drug interaction coefficient (CDI) between doxorubicin and HSP90 inhibitor (IPI-504) in MDA-MB-231 cells. According to the cell survival rate calculations from the CCK8 assay, the CDI value is 1.17, indicating that doxorubicin and IPI-504 have no synergistic cytotoxic effect on MDA-MB-231 cells. ( C ) Calculation of CDI for doxorubicin and HSP70 inhibitor (VER-155008) in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.61, indicating that doxorubicin and VER-155008 exhibit a significant synergistic cytotoxic effect on MDA-MB-231 cells. ( D ) Calculation of CDI between doxorubicin and the LOX inhibitor BAPN in MDA-MB-231 cells. According to the CCK8 assay cell survival rate calculations, the CDI value is 1.14, indicating that doxorubicin and BAPN had no drug synergistic cytotoxic effect on MDA-MB-231 cells. ( E ) Calculation of CDI between doxorubicin and FK886 in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.94, indicating that doxorubicin and FK886 had a synergistic cytotoxic effect on MDA-MB-231 cells.
    Fk886, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fk886/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    fk886 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    fk886  (Millipore)
    90
    Millipore fk886
    Comparison of the survival rate differences in the breast cancer cell line MDA-MB-231 after co-treatment with various misfolding p53 aggregation inhibitors and doxorubicin. ( A ) Cells were treated with the chemotherapy drug doxorubicin (DOX, 1 μM) and the following concentrations of each misfolding p53 aggregation inhibitor: HSP90 inhibitor (IPI-504, 5 μM), HSP70 inhibitor (VER-155008, 10 μM), LOX inhibitor (BAPN, 100 μM), and NAMPT inhibitor <t>(FK886,</t> 10 μM). After 48 h of drug treatment, cell survival rates were assessed using CCK8 reagent. DMSO only was calculated as 100% to normalize other treatment conditions. Results are presented as mean ± SD, n = 3 (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., p > 0.05). ( B ) Calculation of the drug interaction coefficient (CDI) between doxorubicin and HSP90 inhibitor (IPI-504) in MDA-MB-231 cells. According to the cell survival rate calculations from the CCK8 assay, the CDI value is 1.17, indicating that doxorubicin and IPI-504 have no synergistic cytotoxic effect on MDA-MB-231 cells. ( C ) Calculation of CDI for doxorubicin and HSP70 inhibitor (VER-155008) in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.61, indicating that doxorubicin and VER-155008 exhibit a significant synergistic cytotoxic effect on MDA-MB-231 cells. ( D ) Calculation of CDI between doxorubicin and the LOX inhibitor BAPN in MDA-MB-231 cells. According to the CCK8 assay cell survival rate calculations, the CDI value is 1.14, indicating that doxorubicin and BAPN had no drug synergistic cytotoxic effect on MDA-MB-231 cells. ( E ) Calculation of CDI between doxorubicin and FK886 in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.94, indicating that doxorubicin and FK886 had a synergistic cytotoxic effect on MDA-MB-231 cells.
    Fk886, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fk886/product/Millipore
    Average 90 stars, based on 1 article reviews
    fk886 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    fk886  (Astellas)
    90
    Astellas fk886
    Comparison of the survival rate differences in the breast cancer cell line MDA-MB-231 after co-treatment with various misfolding p53 aggregation inhibitors and doxorubicin. ( A ) Cells were treated with the chemotherapy drug doxorubicin (DOX, 1 μM) and the following concentrations of each misfolding p53 aggregation inhibitor: HSP90 inhibitor (IPI-504, 5 μM), HSP70 inhibitor (VER-155008, 10 μM), LOX inhibitor (BAPN, 100 μM), and NAMPT inhibitor <t>(FK886,</t> 10 μM). After 48 h of drug treatment, cell survival rates were assessed using CCK8 reagent. DMSO only was calculated as 100% to normalize other treatment conditions. Results are presented as mean ± SD, n = 3 (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., p > 0.05). ( B ) Calculation of the drug interaction coefficient (CDI) between doxorubicin and HSP90 inhibitor (IPI-504) in MDA-MB-231 cells. According to the cell survival rate calculations from the CCK8 assay, the CDI value is 1.17, indicating that doxorubicin and IPI-504 have no synergistic cytotoxic effect on MDA-MB-231 cells. ( C ) Calculation of CDI for doxorubicin and HSP70 inhibitor (VER-155008) in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.61, indicating that doxorubicin and VER-155008 exhibit a significant synergistic cytotoxic effect on MDA-MB-231 cells. ( D ) Calculation of CDI between doxorubicin and the LOX inhibitor BAPN in MDA-MB-231 cells. According to the CCK8 assay cell survival rate calculations, the CDI value is 1.14, indicating that doxorubicin and BAPN had no drug synergistic cytotoxic effect on MDA-MB-231 cells. ( E ) Calculation of CDI between doxorubicin and FK886 in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.94, indicating that doxorubicin and FK886 had a synergistic cytotoxic effect on MDA-MB-231 cells.
    Fk886, supplied by Astellas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fk886/product/Astellas
    Average 90 stars, based on 1 article reviews
    fk886 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Comparison of the survival rate differences in the breast cancer cell line MDA-MB-231 after co-treatment with various misfolding p53 aggregation inhibitors and doxorubicin. ( A ) Cells were treated with the chemotherapy drug doxorubicin (DOX, 1 μM) and the following concentrations of each misfolding p53 aggregation inhibitor: HSP90 inhibitor (IPI-504, 5 μM), HSP70 inhibitor (VER-155008, 10 μM), LOX inhibitor (BAPN, 100 μM), and NAMPT inhibitor (FK886, 10 μM). After 48 h of drug treatment, cell survival rates were assessed using CCK8 reagent. DMSO only was calculated as 100% to normalize other treatment conditions. Results are presented as mean ± SD, n = 3 (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., p > 0.05). ( B ) Calculation of the drug interaction coefficient (CDI) between doxorubicin and HSP90 inhibitor (IPI-504) in MDA-MB-231 cells. According to the cell survival rate calculations from the CCK8 assay, the CDI value is 1.17, indicating that doxorubicin and IPI-504 have no synergistic cytotoxic effect on MDA-MB-231 cells. ( C ) Calculation of CDI for doxorubicin and HSP70 inhibitor (VER-155008) in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.61, indicating that doxorubicin and VER-155008 exhibit a significant synergistic cytotoxic effect on MDA-MB-231 cells. ( D ) Calculation of CDI between doxorubicin and the LOX inhibitor BAPN in MDA-MB-231 cells. According to the CCK8 assay cell survival rate calculations, the CDI value is 1.14, indicating that doxorubicin and BAPN had no drug synergistic cytotoxic effect on MDA-MB-231 cells. ( E ) Calculation of CDI between doxorubicin and FK886 in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.94, indicating that doxorubicin and FK886 had a synergistic cytotoxic effect on MDA-MB-231 cells.

    Journal: Biomedicines

    Article Title: Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells

    doi: 10.3390/biomedicines13051034

    Figure Lengend Snippet: Comparison of the survival rate differences in the breast cancer cell line MDA-MB-231 after co-treatment with various misfolding p53 aggregation inhibitors and doxorubicin. ( A ) Cells were treated with the chemotherapy drug doxorubicin (DOX, 1 μM) and the following concentrations of each misfolding p53 aggregation inhibitor: HSP90 inhibitor (IPI-504, 5 μM), HSP70 inhibitor (VER-155008, 10 μM), LOX inhibitor (BAPN, 100 μM), and NAMPT inhibitor (FK886, 10 μM). After 48 h of drug treatment, cell survival rates were assessed using CCK8 reagent. DMSO only was calculated as 100% to normalize other treatment conditions. Results are presented as mean ± SD, n = 3 (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., p > 0.05). ( B ) Calculation of the drug interaction coefficient (CDI) between doxorubicin and HSP90 inhibitor (IPI-504) in MDA-MB-231 cells. According to the cell survival rate calculations from the CCK8 assay, the CDI value is 1.17, indicating that doxorubicin and IPI-504 have no synergistic cytotoxic effect on MDA-MB-231 cells. ( C ) Calculation of CDI for doxorubicin and HSP70 inhibitor (VER-155008) in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.61, indicating that doxorubicin and VER-155008 exhibit a significant synergistic cytotoxic effect on MDA-MB-231 cells. ( D ) Calculation of CDI between doxorubicin and the LOX inhibitor BAPN in MDA-MB-231 cells. According to the CCK8 assay cell survival rate calculations, the CDI value is 1.14, indicating that doxorubicin and BAPN had no drug synergistic cytotoxic effect on MDA-MB-231 cells. ( E ) Calculation of CDI between doxorubicin and FK886 in MDA-MB-231 cells. Based on the cell survival rate calculations from the CCK8 assay, the CDI value is 0.94, indicating that doxorubicin and FK886 had a synergistic cytotoxic effect on MDA-MB-231 cells.

    Article Snippet: Cells were treated with DMSO alone, 1 μM Doxorubicin (Sigma-Aldrich, St. Louis, MO, USA), 5 μM IPI-504 (HSP90 inhibitor, MedChemExpress, Monmouth Junction, NJ, USA), 10 μM VER-155008 (HSP70 inhibitor, MedChemExpress), 100 μM BAPN (LOX inhibitor, MedChemExpress), 5 μM FK886 (NAMPT inhibitor, MedChemExpress), or 20 μM z-VAD-FMK (pan-caspase inhibitor, MedChemExpress).

    Techniques: Comparison, CCK-8 Assay